학술논문
The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance
Document Type
Article
Author
Source
In: Antiviral Research . (Antiviral Research, May 2024, 225)
Subject
Language
English
ISSN
18729096
01663542
01663542